<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">ScientificWorldJournal</journal-id><journal-id journal-id-type="iso-abbrev">ScientificWorldJournal</journal-id><journal-id journal-id-type="publisher-id">TSWJ</journal-id><journal-title-group><journal-title>The Scientific World Journal</journal-title></journal-title-group><issn pub-type="ppub">2356-6140</issn><issn pub-type="epub">1537-744X</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24672331</article-id><article-id pub-id-type="pmc">3929062</article-id><article-id pub-id-type="doi">10.1155/2014/565367</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Atorvastatin Combining with Probucol: A New Way to Reduce Serum Uric Acid Level during Perioperative Period of Interventional Procedure</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Li</surname><given-names>Hong</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Ximing</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Hongjun</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yiran</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Naikuan</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Dongxia</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cong</surname><given-names>Hongliang</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Graduate School, Tianjin Medical University, Tianjin 300051, China</aff><aff id="I2">
<sup>2</sup>Department of Geriatrics, The First Hospital of Qinhuangdao, Qinhuangdao 066000, China</aff><aff id="I3">
<sup>3</sup>Department of Cardiology, Tianjin Chest Hospital, Tianjin Medical University, Xi'an Road No. 93, Heping District, Tianjin, 300051, China</aff><aff id="I4">
<sup>4</sup>Cardiology Department, Dagang Oil Field General Hospital, Tianjin Medical University, Tianjin 300051, China</aff><author-notes><corresp id="cor1">*Hongliang Cong: <email>hongliangcong@126.com</email></corresp><fn fn-type="other"><p>Academic Editors: C. L. Athanasuleas, H. Kitabata, and Y. Murakawa</p></fn></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>29</day><month>1</month><year>2014</year></pub-date><volume>2014</volume><elocation-id>565367</elocation-id><history><date date-type="received"><day>19</day><month>8</month><year>2013</year></date><date date-type="accepted"><day>4</day><month>11</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Hong Li et al.</copyright-statement><copyright-year>2014</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Uric acid has ever been considered as one of contrast induced acute kidney injury's risk factors. Atorvastatin and probucol can both improve contrast induced acute kidney injury separately. This prospective study is to assess their effect on reducing serum uric acid level and contrast induced acute kidney injury during perioperative period of interventional procedure. On the basis of different doses of atorvastatin and probucol, 208 cases admitted for coronary angiography or percutaneous coronary intervention were randomly classified into standard combined group (S-C group), intensive combined group (I-C group), and intensive atorvastatin group (I-A group). Patients' blood urea nitrogen, serum creatinine, and serum uric acid were measured and estimated glomerular filtration rate was evaluated 24 hours before and after the procedure. After procedure, blood urea nitrogen in all the three groups decreased; Scr of S-C group and I-A group increased significantly, while estimated glomerular filtration decreased in the S-C group (<italic>P</italic> &#x0003c; 0.05); serum uric acid in S-C group and I-C group decreased significantly (<italic>P</italic> &#x0003c; 0.05). Combination treatment of atorvastatin and probucol before intervention could reduce perioperative serum uric acid level; meanwhile, the intensive combined treatment can improve the contrast induced acute kidney injury. The result was the same for hypertensive patients.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Contrast induced acute kidney injury (CI-AKI) is reported to be the third leading cause of in-hospital acute renal failure [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B3" ref-type="bibr">3</xref>]. Serum uric acid (SUA) could stimulate renin-angiotensin-aldosterone system [<xref rid="B4" ref-type="bibr">4</xref>], which plays an important role in the pathogenesis of CI-AKI. Hyperuricemia has ever been considered as its risk factor [<xref rid="B5" ref-type="bibr">5</xref>]. Recently, researches have shown that atorvastatin and probucol could improve CI-AKI separately [<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B8" ref-type="bibr">8</xref>]. However, little is known about the effect of pretreatment with atorvastatin combined with probucol on SUA level in patients who experience coronary angiography (CAG) or percutaneous coronary intervention (PCI). Therefore, in this study, we investigated the effects of different doses of atorvastatin combined with fixed dose of probucol on the level of SUA and its role in improving CI-AKI.</p></sec><sec id="sec2"><title>2. Material and Methods</title><sec id="sec2.1"><title>2.1. Patients</title><p>From May 2010 till December 2010, two hundred and eight patients who underwent CAG or PCI for coronary heart disease in Tianjin Chest Hospital of China were evaluated consecutively. Blood urea nitrogen (BUN), serum creatinine (Scr), and serum uric acid (SUA) were measured before operation. Estimated glomerular filtration rate (eGFR) was estimated using the modified diet in renal disease (MDRD) study formula. The study population was randomly assigned into three groups: standard combined treatment group (S-C group, <italic>n</italic> = 55), intensive combined treatment group (I-C group, <italic>n</italic> = 79), and intensive atorvastatin therapy group (I-A group, <italic>n</italic> = 74).</p></sec><sec id="sec2.2"><title>2.2. Diagnosis Criteria</title><p>Diagnosis criteria of coronary heart disease in accordance with the 2007 Chinese chronic stable angina pectoris diagnosis and treatment guidelines [<xref rid="B9" ref-type="bibr">9</xref>], 2007 Chinese unstable angina and non-ST segment elevation myocardial infarction diagnosis and treatment guidelines [<xref rid="B10" ref-type="bibr">10</xref>], and universal definition of myocardial infarction in 2008 [<xref rid="B11" ref-type="bibr">11</xref>]. CI-AKI is defined as a postprocedural increase in serum creatinine of &#x02265;44.2&#x02009;<italic>&#x003bc;</italic>mol/L (0.5&#x02009;mg/dL) or &#x0003e;25% from baseline [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>].</p></sec><sec id="sec2.3"><title>2.3. Study Design</title><p>The hypotonic nonionic contrast media iopamidol injection (ShangHai boLecco, Xinyi Pharmaceutical Co., Ltd.) was used in patients. Baseline clinical and procedural characteristics were collected before procedure including the age, gender, body mass index, history of hypertension, and diabetes; the biochemical indicators such as lipid profile and blood glucose were measured, and all patients' followup BUN, Scr, and SUA were tested 24 hours before and 24 hours after the procedure. All patients received the treatment of aspirin, clopidogrel, heparin, nitrate, angiotensin converting enzyme inhibitor (ACEI), and <italic>&#x003b2;</italic> blockers after admission. All eligible patients started to receive atorvastatin or atorvastatin with probucol 1-2 days before operation. The S-C group took atorvastatin 20&#x02009;mg qn and probucol 0.25&#x02009;g tid, with no loading dose intake before procedure; the I-C group took atorvastatin 40&#x02009;mg qn and probucol 0.25&#x02009;g tid, with a loading dose of atorvastatin 40&#x02009;mg and probucol 0.5&#x02009;g 2 hours before the operation; the I-A group took atorvastatin 40&#x02009;mg qn, with a loading dose of atorvastatin 40&#x02009;mg 2 hours before the operation. After the procedure, they continued to take the same doses of atorvastatin and probucol. All patients received hydration therapy with normal saline at a rate of 1&#x02009;mL&#x000b7;kg<sup>&#x02212;1</sup>&#x000b7;h<sup>&#x02212;1</sup> for 6 hours before and 6 hours after procedure. The study was approved by the medical ethics committee of Tianjin Chest Hospital of China. All patients provided written informed consent, and the study was carried out in accordance with the Declaration of Helsinki.</p></sec><sec id="sec2.4"><title>2.4. Exclusion Criteria</title><p>Patients who underwent PCI for acute myocardial infarction were excluded. The other exclusion criteria included alanine transaminase &#x02265;80&#x02009;U/L, serum creatinine &#x0003e; 264&#x02009;<italic>&#x003bc;</italic>mol/L, cancer patients, blood diseases or autoimmune diseases, cardiogenic shock, and left ventricular ejection fraction &#x02264;30%, gout, history of hypersensitivity to contrast media, atorvastatin or probucol, prolonged QT interval (corrected QT interval &#x0003e; 0.44&#x02009;s), previous contrast media exposure within 7 days of study entry, pregnancy, or lactation. Also, patients who had used diuretics during hospitalization or used probenecid, benzbromarone, or allopurinol which affect SUA were excluded. Furthermore, patients who had used statins or probucol within 30 days or had used <italic>N</italic>-acetylcysteine or nonsteroidal anti-inflammatory drugs were all excluded.</p></sec><sec id="sec2.5"><title>2.5. Statistical Analysis</title><p>Statistical analysis was performed using the SPSS (version 17.0). Continuous data were reported as mean &#x000b1; standard deviation. Main statistical indicators were tested for normality and homogeneity of variance. The <italic>t</italic>-test of paired samples was used to compare differences within groups following an intervention. Analysis of variance was used to compare differences among various groups; in addition, the method of Students-Newman-Keuls (SNK) was used to reveal the differences among groups. Categorical data were presented as percentages. Chi-square test was performed for the comparison of categorical variables as priority. A <italic>P</italic> value of &#x0003c;0.05 (2-sided) was considered to reflect statistical significance.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Patients and Baseline Characteristics</title><p>The baseline data are shown in <xref ref-type="table" rid="tab1">Table 1</xref>.</p></sec><sec id="sec3.2"><title>3.2. Markers of Renal Function (the Change of Scr, BUN, and eGFR between Three Groups)</title><p>Baseline renal function including BUN, Scr, SUA, and eGFR of the three groups were similar (<italic>P</italic> &#x0003e; 0.05). After operation, BUN in all groups decreased; Scr in S-C group and I-A group increased significantly, while only the S-C group's eGFR decreased (<italic>P</italic> &#x0003c; 0.05); there were no significant differences in Scr and eGFR of I-C group after the procedure (<italic>P</italic> &#x0003e; 0.05). SUA in S-C group and I-C group decreased significantly after operation (<italic>P</italic> &#x0003c; 0.05), while no significant difference was observed in I-A group (<italic>P</italic> &#x0003e; 0.05). The absolute change of UA (&#x00394;UA) in S-C group and in I-C group was significantly higher than I-A group (both <italic>P</italic> &#x0003c; 0.05). There were two patients who suffered from CIAKI; one was in S-C group and the other was in I-C group (<xref ref-type="table" rid="tab2">Table 2</xref>).</p></sec><sec id="sec3.3"><title>3.3. Postoperation Changes of Renal Parameters in the Hypertension Subgroup</title><p>According to ESH and ESC Guidelines of Hypertension [<xref rid="B14" ref-type="bibr">14</xref>] in 2007, we selected 140 hypertensive patients to analyze changes of renal parameters before and after operation in the subgroup. eGFR in S-C group and I-A group decreased significantly (<italic>P</italic> &#x0003c; 0.05), while SUA showed no significant difference in the two groups; in I-C group, BUN and SUA decreased markedly (<italic>P</italic> &#x0003c; 0.05), while Scr and eGFR showed no significant changes (<xref ref-type="table" rid="tab3">Table 3</xref>).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>Intravascular administration of iodinated contrast media gives rise to a potential danger of renal hemodynamic instability as a cause of renal ischemia, hypoxia, and oxidative inflammatory response, thus bringing about impaired renal function [<xref rid="B15" ref-type="bibr">15</xref>]. Retrospective studies have reported CI-AKI incidence ranging from 1.5% to 10% of general population, while the incidence increased to 30&#x02013;50% with high risk factors such as chronic renal insufficiency, diabetes, and hypertension [<xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>]. In our study, two patients suffered CI-AKI, occurred in 0.96% (2 of 208) of the overall studied population. The lower incidence was probably for the reason that we only examined serum creatinine level once after operation. Uric acid is greatly important in the pathogenesis of CI-AKI. It has been suggested that tubular obstruction by uric acid plays a role in the pathogenesis of CI-AKI [<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>]. Furthermore, hyperuricemia is accompanied by enhanced synthesis of reactive oxygen species, an activated renin-angiotensin-aldosterone system, increased endothelin-1, and inhibited nitric oxide system [<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>], which results in strong constriction of blood vessels further reducing the blood flow to the renal medulla. In addition, xanthine oxidase is an important source of superoxide free radicals, which plays a crucial role to increase the production and activity of uric acid. Elevated uric acid, accompanied with inflammatory reaction and oxidative stress, is involved in the pathogenesis of CI-AKI [<xref rid="B23" ref-type="bibr">23</xref>]. Toprak et al. [<xref rid="B5" ref-type="bibr">5</xref>] reported that in a total of 266 patients with Scr &#x02265;1.2&#x02009;mg/dL who underwent coronary angiography, CI-AKI occurred at 15.1% in the hyperuricemic group and 2.9% in the normouricemic group (<italic>P</italic> &#x0003c; 0.001). Recent epidemiologic and experimental evidence suggests the role of SUA is not only an independent cardiovascular risk factor [<xref rid="B24" ref-type="bibr">24</xref>] but also a causal risk factor for the development and progression of renal disease. Elevated levels of uric acid independently increase the risk of new-onset kidney disease [<xref rid="B25" ref-type="bibr">25</xref>]. Hyperuricemia is associated with the disease occurrence of vital organs such as blood vessels, heart, and kidneys. Therefore, reducing uric acid is expected to be a new way to prevent cardiovascular disease. Epidemiologic studies suggest that high level of SUA is an independent risk factor of hypertension [<xref rid="B26" ref-type="bibr">26</xref>]. Hypertensive nephropathy may increase the level of SUA. Hypertension complicated with hyperuricemia could affect each other, resulting in renal function damage.</p><p>The prophylactic effects of statin treatment on the development of CI-AKI are still controversial. The recent systemic review and meta-analysis have not provided conclusive result [<xref rid="B27" ref-type="bibr">27</xref>]. Under the fixed-effects model, a nonsignificant protective trend toward decreased incidence of CIN with periprocedural short-term high-dose statin treatment was seen (RR: 0.70; 95% CI: 0.48&#x02013;1.02). Nevertheless, there is a great body of studies that have proved that statin treatment can effectively prevent CI-AKI [<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>]. In Su et al.'s study [<xref rid="B30" ref-type="bibr">30</xref>], multivariate logistic regression analysis showed that pretreatment with high dose atorvastatin was a protective factor for post-CI-AKI (20&#x02009;mg atorvastatin: <italic>P</italic> = 0.001; 40&#x02009;mg atorvastatin: <italic>P</italic> = 0.001). The mechanism may be that atorvastatin can improve eGFR, remove free radicals, inhibit the inflammatory response [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>], and reduce uric acid level by increasing its excretion [<xref rid="B33" ref-type="bibr">33</xref>]. Probucol plays a significant role in improving the CI-AKI owing to clearing oxygen free radicals, against oxidative stress, thus improving endothelial function [<xref rid="B8" ref-type="bibr">8</xref>]. Currently, there is a lack of large-scale researches about the effect on SUA of atorvastatin combined with probucol intake during perioperative intervention. Our small sample research suggested that a certain dose of atorvastatin and probucol intake in short-term preoperatively can decrease the perioperative SUA level significantly. The BUN in I-C group decreased, while there was no significant difference in Scr and eGFR. The SUA in I-A group did not decrease, while the Scr increased without eGFR decreasing. The analysis of hypertensive subgroup suggested that intensive atorvastatin and probucol combination did not change postoperative Scr and eGFR significantly, but could reduce perioperative SUA level significantly. According to our study, combination treatment of atorvastatin and probucol before intervention could reduce perioperative SUA level; further the intensive combined treatment can improve CI-AKI. For hypertensive patients, combination and intensive treatment could reduce SUA level and improve the CI-AKI. Thus, patients with coronary heart disease or hypertension who are undergoing the intervention may benefit from the combined medication by reducing the uric acid level and improving CI-AKI.</p><p>The major limitations of the present study were the short duration of observation and having a small sample. Also, this was a single-center observational clinical study. Large sample and multicenter trials ought to be designed to verify the conclusion.</p></sec></body><back><ack><title>Acknowledgments</title><p>This paper was supported by a grant from Tianjin Science and Technology Support Plan Key Project (12ZCZDSY03200) and Tianjin Bureau of Public Health's Strategic Scientific &#x00026; Technology Fund (nos. 10KG122, 2011KZ64, and 12KG127).</p></ack><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors have no competing interests.</p></sec><sec><title>Authors' Contribution</title><p>Hong Li and Ximing Li are co-first authors for this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullough</surname><given-names>PA</given-names></name><name><surname>Soman</surname><given-names>SS</given-names></name></person-group><article-title>Contrast-induced nephropathy</article-title><source><italic>Critical Care Clinics</italic></source><year>2005</year><volume>21</volume><issue>2</issue><fpage>261</fpage><lpage>280</lpage><pub-id pub-id-type="other">2-s2.0-15244341062</pub-id><pub-id pub-id-type="pmid">15781162</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Persson</surname><given-names>PB</given-names></name><name><surname>Hansell</surname><given-names>P</given-names></name><name><surname>Liss</surname><given-names>P</given-names></name></person-group><article-title>Pathophysiology of contrast medium-induced nephropathy</article-title><source><italic>Kidney International</italic></source><year>2005</year><volume>68</volume><issue>1</issue><fpage>14</fpage><lpage>22</lpage><pub-id pub-id-type="other">2-s2.0-24944514021</pub-id><pub-id pub-id-type="pmid">15954892</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Detrenis</surname><given-names>S</given-names></name><name><surname>Meschi</surname><given-names>M</given-names></name><name><surname>Musini</surname><given-names>S</given-names></name><name><surname>Savazzi</surname><given-names>G</given-names></name></person-group><article-title>Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art</article-title><source><italic>Nephrology Dialysis Transplantation</italic></source><year>2005</year><volume>20</volume><issue>8</issue><fpage>1542</fpage><lpage>1550</lpage><pub-id pub-id-type="other">2-s2.0-26444608615</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlstein</surname><given-names>TS</given-names></name><name><surname>Gumieniak</surname><given-names>O</given-names></name><name><surname>Hopkins</surname><given-names>PN</given-names></name><etal/></person-group><article-title>Uric acid and the state of the intrarenal renin-angiotensin system in humans</article-title><source><italic>Kidney International</italic></source><year>2004</year><volume>66</volume><issue>4</issue><fpage>1465</fpage><lpage>1470</lpage><pub-id pub-id-type="other">2-s2.0-4644243534</pub-id><pub-id pub-id-type="pmid">15458439</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toprak</surname><given-names>O</given-names></name><name><surname>Cirit</surname><given-names>M</given-names></name><name><surname>Esi</surname><given-names>E</given-names></name><name><surname>Postaci</surname><given-names>N</given-names></name><name><surname>Yesil</surname><given-names>M</given-names></name><name><surname>Bayata</surname><given-names>S</given-names></name></person-group><article-title>Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease</article-title><source><italic>Catheterization and Cardiovascular Interventions</italic></source><year>2006</year><volume>67</volume><issue>2</issue><fpage>227</fpage><lpage>235</lpage><pub-id pub-id-type="other">2-s2.0-32544452416</pub-id><pub-id pub-id-type="pmid">16400673</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zhan</surname><given-names>H</given-names></name><name><surname>Erden</surname><given-names>I</given-names></name><name><surname>Ordu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography</article-title><source><italic>Angiology</italic></source><year>2010</year><volume>61</volume><issue>7</issue><fpage>711</fpage><lpage>714</lpage><pub-id pub-id-type="other">2-s2.0-77956467157</pub-id><pub-id pub-id-type="pmid">20395226</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>J</given-names></name><name><surname>Kastelein</surname><given-names>JJ</given-names></name><name><surname>Bittner</surname><given-names>V</given-names></name><etal/></person-group><article-title>Effects of intensive lipid lowering with atorvastatinon renal function: the treating to new targets study</article-title><source><italic>Clinical Journal of the American Society of Nephrology</italic></source><year>2007</year><volume>2</volume><issue>6</issue><fpage>1131</fpage><lpage>1139</lpage><pub-id pub-id-type="pmid">17942759</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>G-P</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Role of probucol in preventing contrast induced acute kidney injury after coronary interventional procedure: a randomized trial</article-title><source><italic>Chinese Journal of Cardiovascular Diseases</italic></source><year>2009</year><volume>37</volume><issue>5</issue><fpage>385</fpage><lpage>388</lpage><pub-id pub-id-type="other">2-s2.0-73949093107</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><collab>Cardiovascular branch of Chinese Medical Association</collab><article-title>chronic stable angina pectoris diagnosis and treatment guidelines</article-title><source><italic>Chinese Journal of Cardiology</italic></source><year>2007</year><volume>35</volume><issue>3</issue><fpage>195</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">17582280</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><collab>Cardiovascular branch of Chinese Medical Association</collab><article-title>Unstable angina and non ST segment elevation myocardial infarction diagnosis and treatment guidelines</article-title><source><italic>Chinese Journal of Cardiology</italic></source><year>2007</year><volume>35</volume><issue>3</issue><fpage>295</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">17711651</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><collab>Cardiovascular branch of Chinese Medical Association</collab><article-title>Recommendation the use of universal definition of myocardial infarction in China</article-title><source><italic>Chinese Journal of Cardiology</italic></source><year>2008</year><volume>36</volume><issue>10</issue><fpage>867</fpage><lpage>869</lpage><pub-id pub-id-type="pmid">19102880</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehran</surname><given-names>R</given-names></name><name><surname>Kahn</surname><given-names>J</given-names></name></person-group><article-title>Contrast-induced nephropathy remains a serious complication of PCI</article-title><source><italic>Journal of Interventional Cardiology</italic></source><year>2007</year><volume>20</volume><issue>3</issue><fpage>236</fpage><lpage>240</lpage><pub-id pub-id-type="other">2-s2.0-34249336737</pub-id><pub-id pub-id-type="pmid">17524117</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullough</surname><given-names>PA</given-names></name></person-group><article-title>Beyond serum creatinine: defining the patient with renal insufficiency and why?</article-title><source><italic>Reviews in Cardiovascular Medicine</italic></source><year>2003</year><volume>4</volume><issue>supplement 1</issue><fpage>S2</fpage><lpage>S6</lpage><pub-id pub-id-type="other">2-s2.0-0037242058</pub-id><pub-id pub-id-type="pmid">12556731</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><collab>The task force for he management of arterial hypertension of the European Society of hypertension (ESH) and of the European Society of Cardiology (ESC)</collab><article-title>2007 Guidelines for the management of arterial hypertension</article-title><source><italic>Journal of Hypertension</italic></source><year>2007</year><volume>25</volume><issue>6</issue><fpage>1105</fpage><lpage>1187</lpage><pub-id pub-id-type="pmid">17563527</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sterling</surname><given-names>KA</given-names></name><name><surname>Tehrani</surname><given-names>T</given-names></name><name><surname>Rudnick</surname><given-names>MR</given-names></name></person-group><article-title>Clinical significance and preventive strategies for contrast-induced nephropathy</article-title><source><italic>Current Opinion in Nephrology and Hypertension</italic></source><year>2008</year><volume>17</volume><issue>6</issue><fpage>616</fpage><lpage>623</lpage><pub-id pub-id-type="other">2-s2.0-56249110201</pub-id><pub-id pub-id-type="pmid">18941356</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amini</surname><given-names>M</given-names></name><name><surname>Salarifar</surname><given-names>M</given-names></name><name><surname>Amirbaigloo</surname><given-names>A</given-names></name><name><surname>Masoudkabir</surname><given-names>F</given-names></name><name><surname>Esfahani</surname><given-names>F</given-names></name></person-group><article-title>N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial</article-title><source><italic>Trials</italic></source><year>2009</year><volume>10, article 45</volume><pub-id pub-id-type="other">2-s2.0-68349100010</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>SW</given-names></name><name><surname>Barrett</surname><given-names>BJ</given-names></name><name><surname>Parfrey</surname><given-names>PS</given-names></name></person-group><article-title>Contrast nephropathy</article-title><source><italic>Journal of the American Society of Nephrology</italic></source><year>2000</year><volume>11</volume><issue>1</issue><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="other">2-s2.0-0033982499</pub-id><pub-id pub-id-type="pmid">10616853</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gleeson</surname><given-names>TG</given-names></name><name><surname>Bulugahapitiya</surname><given-names>S</given-names></name></person-group><article-title>Contrast-induced nephropathy</article-title><source><italic>The American Journal of Roentgenology</italic></source><year>2004</year><volume>183</volume><issue>6</issue><fpage>1673</fpage><lpage>1689</lpage><pub-id pub-id-type="other">2-s2.0-16644390328</pub-id><pub-id pub-id-type="pmid">15547209</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postlethwaite</surname><given-names>AE</given-names></name><name><surname>Kelley</surname><given-names>WN</given-names></name></person-group><article-title>Uricosuric effect of radiocontrast agents: a study in man of four commonly used preparations</article-title><source><italic>Annals of Internal Medicine</italic></source><year>1971</year><volume>74</volume><issue>6</issue><fpage>845</fpage><lpage>852</lpage><pub-id pub-id-type="other">2-s2.0-0015074058</pub-id><pub-id pub-id-type="pmid">5580635</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mudge</surname><given-names>GH</given-names></name></person-group><article-title>Uricosuric action of cholecystographic agents: a possible factor in nephrotoxicity</article-title><source><italic>The New England Journal of Medicine</italic></source><year>1971</year><volume>284</volume><issue>17</issue><fpage>929</fpage><lpage>933</lpage><pub-id pub-id-type="other">2-s2.0-0015244180</pub-id><pub-id pub-id-type="pmid">5551801</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>D-H</given-names></name><name><surname>Yu</surname><given-names>ES</given-names></name><name><surname>Park</surname><given-names>J-E</given-names></name><etal/></person-group><article-title>Uric acid induced C-reactive protein expression via upregulation of angiotensin type 1 receptors in vascular endothelial cells and smooth muscle cells</article-title><source><italic>Journal of the American Society of Nephrology</italic></source><year>2005</year><volume>16</volume><issue>12</issue><fpage>3553</fpage><lpage>3562</lpage><pub-id pub-id-type="pmid">16251237</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>RJ</given-names></name><name><surname>Kang</surname><given-names>D-H</given-names></name><name><surname>Feig</surname><given-names>D</given-names></name><etal/></person-group><article-title>Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?</article-title><source><italic>Hypertension</italic></source><year>2003</year><volume>41</volume><issue>6</issue><fpage>1183</fpage><lpage>1190</lpage><pub-id pub-id-type="other">2-s2.0-0038119701</pub-id><pub-id pub-id-type="pmid">12707287</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruggiero</surname><given-names>C</given-names></name><name><surname>Cherubini</surname><given-names>A</given-names></name><name><surname>Ble</surname><given-names>A</given-names></name><etal/></person-group><article-title>Uric acid and inflammatory markers</article-title><source><italic>European Heart Journal</italic></source><year>2006</year><volume>27</volume><issue>10</issue><fpage>1174</fpage><lpage>1181</lpage><pub-id pub-id-type="other">2-s2.0-33646748459</pub-id><pub-id pub-id-type="pmid">16611671</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bos</surname><given-names>MJ</given-names></name><name><surname>Koudstaal</surname><given-names>PJ</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Witteman</surname><given-names>JCM</given-names></name><name><surname>Breteler</surname><given-names>MMB</given-names></name></person-group><article-title>Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam Study</article-title><source><italic>Stroke</italic></source><year>2006</year><volume>37</volume><issue>6</issue><fpage>1503</fpage><lpage>1507</lpage><pub-id pub-id-type="other">2-s2.0-33745144316</pub-id><pub-id pub-id-type="pmid">16675740</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obermayr</surname><given-names>RP</given-names></name><name><surname>Temml</surname><given-names>C</given-names></name><name><surname>Gutjahr</surname><given-names>G</given-names></name><name><surname>Knechtelsdorfer</surname><given-names>M</given-names></name><name><surname>Oberbauer</surname><given-names>R</given-names></name><name><surname>Klauser-Braun</surname><given-names>R</given-names></name></person-group><article-title>Elevated uric acid increases the risk for kidney disease</article-title><source><italic>Journal of the American Society of Nephrology</italic></source><year>2008</year><volume>19</volume><issue>12</issue><fpage>2407</fpage><lpage>2413</lpage><pub-id pub-id-type="other">2-s2.0-57149091788</pub-id><pub-id pub-id-type="pmid">18799720</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundstr&#x000f6;m</surname><given-names>J</given-names></name><name><surname>Sullivan</surname><given-names>L</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>RB</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Kannel</surname><given-names>WB</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name></person-group><article-title>Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence</article-title><source><italic>Hypertension</italic></source><year>2005</year><volume>45</volume><issue>1</issue><fpage>28</fpage><lpage>33</lpage><pub-id pub-id-type="other">2-s2.0-11244264034</pub-id><pub-id pub-id-type="pmid">15569852</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Shen</surname><given-names>L-H</given-names></name><name><surname>Hu</surname><given-names>L-H</given-names></name><name><surname>He</surname><given-names>B</given-names></name></person-group><article-title>Statins for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis</article-title><source><italic>The American Journal of Nephrology</italic></source><year>2011</year><volume>33</volume><issue>4</issue><fpage>344</fpage><lpage>351</lpage><pub-id pub-id-type="other">2-s2.0-79952820559</pub-id><pub-id pub-id-type="pmid">21430372</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xinwei</surname><given-names>J</given-names></name><name><surname>Xianghua</surname><given-names>F</given-names></name><name><surname>Jing</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention</article-title><source><italic>The American Journal of Cardiology</italic></source><year>2009</year><volume>104</volume><issue>4</issue><fpage>519</fpage><lpage>524</lpage><pub-id pub-id-type="other">2-s2.0-67849122782</pub-id><pub-id pub-id-type="pmid">19660605</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Jin</surname><given-names>Y-Z</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Min</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>X-Y</given-names></name></person-group><article-title>Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography</article-title><source><italic>Chinese Journal of Cardiovascular Diseases</italic></source><year>2009</year><volume>37</volume><issue>5</issue><fpage>394</fpage><lpage>396</lpage><pub-id pub-id-type="other">2-s2.0-73949119205</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>JZ</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>WQ</given-names></name><etal/></person-group><article-title>Association between high sensitivity C-reactive protein and contrast induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin</article-title><source><italic>Chinese Journal of Cardiovascular Diseases</italic></source><year>2011</year><volume>39</volume><issue>9</issue><fpage>807</fpage><lpage>811</lpage></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khanal</surname><given-names>S</given-names></name><name><surname>Attallah</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions</article-title><source><italic>The American Journal of Medicine</italic></source><year>2005</year><volume>118</volume><issue>8</issue><fpage>843</fpage><lpage>849</lpage><pub-id pub-id-type="other">2-s2.0-23244448755</pub-id><pub-id pub-id-type="pmid">16084176</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patti</surname><given-names>G</given-names></name><name><surname>Nusca</surname><given-names>A</given-names></name><name><surname>Chello</surname><given-names>M</given-names></name><etal/></person-group><article-title>Usefulness of statin pretreatment to prevent contrastinduced nephropathy and to improve long-term outcomes in patients undergoing percutaneous coronary intervention</article-title><source><italic>The American Journal of Cardiology</italic></source><year>2008</year><volume>101</volume><issue>3</issue><fpage>279</fpage><lpage>285</lpage><pub-id pub-id-type="other">2-s2.0-38549127836</pub-id><pub-id pub-id-type="pmid">18237585</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milionis</surname><given-names>HJ</given-names></name><name><surname>Kakafika</surname><given-names>AI</given-names></name><name><surname>Tsouli</surname><given-names>SG</given-names></name><etal/></person-group><article-title>Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia</article-title><source><italic>The American Heart Journal</italic></source><year>2004</year><volume>148</volume><issue>4</issue><fpage>635</fpage><lpage>640</lpage><pub-id pub-id-type="other">2-s2.0-5344244028</pub-id><pub-id pub-id-type="pmid">15459594</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline clinical, biochemical and procedural characteristics of the patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">S-C group<break/> (<italic>n</italic> = 55)</th><th align="center" rowspan="1" colspan="1">I-C group<break/> (<italic>n</italic> = 79)</th><th align="center" rowspan="1" colspan="1">I-A group<break/> (<italic>n</italic> = 74)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (year)</td><td align="center" rowspan="1" colspan="1">62.33 &#x000b1; 9.49</td><td align="center" rowspan="1" colspan="1">60.65 &#x000b1; 10.11</td><td align="center" rowspan="1" colspan="1">61.00 &#x000b1; 10.23</td><td align="center" rowspan="1" colspan="1">0.616<sup>a</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Female gender</td><td align="center" rowspan="1" colspan="1">25 (45.45%)</td><td align="center" rowspan="1" colspan="1">33 (41.72%)</td><td align="center" rowspan="1" colspan="1">27 (36.49%)</td><td align="center" rowspan="1" colspan="1">0.579<sup>b</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">27.24 &#x000b1; 10.23</td><td align="center" rowspan="1" colspan="1">25.96 &#x000b1; 3.51</td><td align="center" rowspan="1" colspan="1">28.35 &#x000b1; 17.26</td><td align="center" rowspan="1" colspan="1">0.454<sup>a</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Current smoking (<italic>n</italic>)</td><td align="center" rowspan="1" colspan="1">19/34.55</td><td align="center" rowspan="1" colspan="1">33/41.77</td><td align="center" rowspan="1" colspan="1">36/48.65</td><td align="center" rowspan="1" colspan="1">0.274<sup>b</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cholesterol (mmol/L)</td><td align="center" rowspan="1" colspan="1">4.81 &#x000b1; 1.21</td><td align="center" rowspan="1" colspan="1">4.91 &#x000b1; 1.59</td><td align="center" rowspan="1" colspan="1">4.68 &#x000b1; 1.27</td><td align="center" rowspan="1" colspan="1">0.592<sup>a</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglyceride (mmol/L)</td><td align="center" rowspan="1" colspan="1">1.83 &#x000b1; 0.96</td><td align="center" rowspan="1" colspan="1">1.71 &#x000b1; 0.78</td><td align="center" rowspan="1" colspan="1">1.67 &#x000b1; 0.93</td><td align="center" rowspan="1" colspan="1">0.553<sup>a</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Low-density lipoprotein (mmol/L)</td><td align="center" rowspan="1" colspan="1">2.74 &#x000b1; 0.92</td><td align="center" rowspan="1" colspan="1">2.98 &#x000b1; 1.32</td><td align="center" rowspan="1" colspan="1">2.72 &#x000b1; 1.02</td><td align="center" rowspan="1" colspan="1">0.291<sup>a</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood glucose (mmol/L)</td><td align="center" rowspan="1" colspan="1">5.66 &#x000b1; 1.56</td><td align="center" rowspan="1" colspan="1">5.62 &#x000b1; 1.71</td><td align="center" rowspan="1" colspan="1">5.65 &#x000b1; 2.00</td><td align="center" rowspan="1" colspan="1">0.993<sup>a</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Red blood cell count (10<sup>12</sup>/L)</td><td align="center" rowspan="1" colspan="1">4.50 &#x000b1; 0.76</td><td align="center" rowspan="1" colspan="1">4.53 &#x000b1; 0.41</td><td align="center" rowspan="1" colspan="1">4.35 &#x000b1; 0.46</td><td align="center" rowspan="1" colspan="1">0.116<sup> a</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">White blood cell count (10<sup>9</sup>/L)</td><td align="center" rowspan="1" colspan="1">6.91 &#x000b1; 1.53</td><td align="center" rowspan="1" colspan="1">7.29 &#x000b1; 1.87</td><td align="center" rowspan="1" colspan="1">7.73 &#x000b1; 1.92</td><td align="center" rowspan="1" colspan="1">0.211<sup>a</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus (<italic>n</italic>)</td><td align="center" rowspan="1" colspan="1">11 (20.00%)</td><td align="center" rowspan="1" colspan="1">23 (29.11%)</td><td align="center" rowspan="1" colspan="1">16 (21.62%)</td><td align="center" rowspan="1" colspan="1">0.398<sup>b</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Volume of contrast agent (mL)</td><td align="center" rowspan="1" colspan="1">187.96 &#x000b1; 103.22</td><td align="center" rowspan="1" colspan="1">185.53 &#x000b1; 142.32</td><td align="center" rowspan="1" colspan="1">185.71 &#x000b1; 123.69</td><td align="center" rowspan="1" colspan="1">0.993<sup> a</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension (<italic>n</italic>)</td><td align="center" rowspan="1" colspan="1">38 (69.09%)</td><td align="center" rowspan="1" colspan="1">53 (67.09%)</td><td align="center" rowspan="1" colspan="1">49 (66.22%)</td><td align="center" rowspan="1" colspan="1">0.548<sup>b</sup>
</td></tr></tbody></table><table-wrap-foot><fn><p>Values are expressed as means &#x000b1; SD or number (%) of patients.<sup> a</sup>By Student's <italic>t</italic> test; <sup>b</sup>By <italic>&#x003c7;</italic>
<sup>2</sup> test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Comparison of serum BUN, Scr, SUA and eGFR levels at baseline and 24 hours after Intervention.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">S-C group</th><th align="center" rowspan="1" colspan="1">I-C group</th><th align="center" rowspan="1" colspan="1">I-A group</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>&#x02032; value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BUN (mmol/L)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="center" rowspan="1" colspan="1">5.66 &#x000b1; 1.48</td><td align="center" rowspan="1" colspan="1">5.58 &#x000b1; 1.29</td><td align="center" rowspan="1" colspan="1">5.27 &#x000b1; 1.27</td><td align="center" rowspan="1" colspan="1">0.203</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Post procedural</td><td align="center" rowspan="1" colspan="1">4.93 &#x000b1; 2.08</td><td align="center" rowspan="1" colspan="1">4.63 &#x000b1; 1.17</td><td align="center" rowspan="1" colspan="1">4.96 &#x000b1; 1.25</td><td align="center" rowspan="1" colspan="1">
&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Absolute change &#x00394;BUN</td><td align="center" rowspan="1" colspan="1">&#x02212;0.72 &#x000b1; 1.77</td><td align="center" rowspan="1" colspan="1">&#x02212;0.95 &#x000b1; 1.24</td><td align="center" rowspan="1" colspan="1">&#x02212;0.31 &#x000b1; 1.32</td><td align="center" rowspan="1" colspan="1">0.022</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;
<italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">0.004</td><td align="center" rowspan="1" colspan="1">0.000</td><td align="center" rowspan="1" colspan="1">0.046</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Scr (umol/L)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="center" rowspan="1" colspan="1">82.45 &#x000b1; 15.48</td><td align="center" rowspan="1" colspan="1">81.77 &#x000b1; 18.37</td><td align="center" rowspan="1" colspan="1">85.83 &#x000b1; 15.45</td><td align="center" rowspan="1" colspan="1">0.287</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Post procedural</td><td align="center" rowspan="1" colspan="1">88.32 &#x000b1; 24.68</td><td align="center" rowspan="1" colspan="1">82.67 &#x000b1; 16.88</td><td align="center" rowspan="1" colspan="1">88.66 &#x000b1; 16.87</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Absolute change &#x00394;Scr</td><td align="center" rowspan="1" colspan="1">5.87 &#x000b1; 19.36</td><td align="center" rowspan="1" colspan="1">0.89 &#x000b1; 12.96</td><td align="center" rowspan="1" colspan="1">2.84 &#x000b1; 9.47</td><td align="center" rowspan="1" colspan="1">0.129</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;
<italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">0.029</td><td align="center" rowspan="1" colspan="1">0.542</td><td align="center" rowspan="1" colspan="1">0.012</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">SUA (mmol/L)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="center" rowspan="1" colspan="1">322.36 &#x000b1; 77.57</td><td align="center" rowspan="1" colspan="1">310.45 &#x000b1; 69.59</td><td align="center" rowspan="1" colspan="1">329.77 &#x000b1; 81.88</td><td align="center" rowspan="1" colspan="1">0.289</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Post procedural</td><td align="center" rowspan="1" colspan="1">299.32 &#x000b1; 72.16</td><td align="center" rowspan="1" colspan="1">281.20 &#x000b1; 62.80</td><td align="center" rowspan="1" colspan="1">328.11 &#x000b1; 90.79</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Absolute change &#x00394;SUA</td><td align="center" rowspan="1" colspan="1">&#x02212;23.04 &#x000b1; 64.80</td><td align="center" rowspan="1" colspan="1">&#x02212;29.25 &#x000b1; 43.07</td><td align="center" rowspan="1" colspan="1">&#x02212;1.66 &#x000b1; 83.03</td><td align="center" rowspan="1" colspan="1">0.028</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;
<italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">0.011</td><td align="center" rowspan="1" colspan="1">0.000</td><td align="center" rowspan="1" colspan="1">0.864</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">
eGFR (mL/min)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="center" rowspan="1" colspan="1">79.12 &#x000b1; 13.49</td><td align="center" rowspan="1" colspan="1">81.64 &#x000b1; 15.70</td><td align="center" rowspan="1" colspan="1">78.67 &#x000b1; 16.19</td><td align="center" rowspan="1" colspan="1">0.444</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Post procedural</td><td align="center" rowspan="1" colspan="1">75.33 &#x000b1; 15.70</td><td align="center" rowspan="1" colspan="1">80.47 &#x000b1; 15.33</td><td align="center" rowspan="1" colspan="1">76.28 &#x000b1; 15.72</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic>P</italic> value was the comparison of the group between Baseline and Post procedural. <italic>P</italic>&#x02032; value was the comparison among groups.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Post-operation changes of renal parameters in the hypertensive subgroup.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">S-C group <break/> (<italic>n</italic> = 38)</th><th align="center" rowspan="1" colspan="1">I-C group <break/> (<italic>n</italic> = 53)</th><th align="center" rowspan="1" colspan="1">I-A group <break/> (<italic>n</italic> = 49)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>&#x02032; value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BUN (mmol/L)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="center" rowspan="1" colspan="1">5.61 &#x000b1; 1.29</td><td align="center" rowspan="1" colspan="1">5.61 &#x000b1; 1.32</td><td align="center" rowspan="1" colspan="1">5.37 &#x000b1; 1.21</td><td align="center" rowspan="1" colspan="1">0.556</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Post procedural</td><td align="center" rowspan="1" colspan="1">4.86 &#x000b1; 1.85</td><td align="center" rowspan="1" colspan="1">4.62 &#x000b1; 0.99</td><td align="center" rowspan="1" colspan="1">5.12 &#x000b1; 1.35</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Absolute change &#x00394;BUN</td><td align="center" rowspan="1" colspan="1">&#x02212;0.74 &#x000b1; 1.85</td><td align="center" rowspan="1" colspan="1">&#x02212;0.99 &#x000b1; 1.17</td><td align="center" rowspan="1" colspan="1">&#x02212;0.25 &#x000b1; 1.23</td><td align="center" rowspan="1" colspan="1">0.027</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;
<italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">0.017</td><td align="center" rowspan="1" colspan="1">0.000</td><td align="center" rowspan="1" colspan="1">0.161</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Scr (<italic>&#x003bc;</italic>mol/L)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="center" rowspan="1" colspan="1">81.85 &#x000b1; 15.80</td><td align="center" rowspan="1" colspan="1">78.60 &#x000b1; 15.34</td><td align="center" rowspan="1" colspan="1">85.37 &#x000b1; 16.26</td><td align="center" rowspan="1" colspan="1">0.100</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Post procedural</td><td align="center" rowspan="1" colspan="1">88.80 &#x000b1; 25.33</td><td align="center" rowspan="1" colspan="1">80.73 &#x000b1; 17.04</td><td align="center" rowspan="1" colspan="1">89.79 &#x000b1; 18.09</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Absolute change &#x00394;Scr</td><td align="center" rowspan="1" colspan="1">6.94 &#x000b1; 21.79</td><td align="center" rowspan="1" colspan="1">2.13 &#x000b1; 12.08</td><td align="center" rowspan="1" colspan="1">4.42 &#x000b1; 9.20</td><td align="center" rowspan="1" colspan="1">0.300</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;
<italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">0.054</td><td align="center" rowspan="1" colspan="1">0.205</td><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">SUA (mmol/L)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="center" rowspan="1" colspan="1">328.93 &#x000b1; 78.64</td><td align="center" rowspan="1" colspan="1">314.88 &#x000b1; 70.97</td><td align="center" rowspan="1" colspan="1">331.88 &#x000b1; 86.54</td><td align="center" rowspan="1" colspan="1">0.512</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Post procedural</td><td align="center" rowspan="1" colspan="1">308.28 &#x000b1; 73.35</td><td align="center" rowspan="1" colspan="1">285.05 &#x000b1; 66.12</td><td align="center" rowspan="1" colspan="1">325.60 &#x000b1; 72.63</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Absolute change &#x00394;SUA</td><td align="center" rowspan="1" colspan="1">&#x02212;20.65 &#x000b1; 65.25</td><td align="center" rowspan="1" colspan="1">&#x02212;29.82 &#x000b1; 45.78</td><td align="center" rowspan="1" colspan="1">&#x02212;6.28 &#x000b1; 68.88</td><td align="center" rowspan="1" colspan="1">0.143</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;
<italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">0.055</td><td align="center" rowspan="1" colspan="1">0.000</td><td align="center" rowspan="1" colspan="1">0.527</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR (mL/min)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="center" rowspan="1" colspan="1">79.68 &#x000b1; 13.14</td><td align="center" rowspan="1" colspan="1">83.29 &#x000b1; 15.29</td><td align="center" rowspan="1" colspan="1">77.87 &#x000b1; 14.91</td><td align="center" rowspan="1" colspan="1">0.165</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Post procedural</td><td align="center" rowspan="1" colspan="1">74.67 &#x000b1; 14.36</td><td align="center" rowspan="1" colspan="1">81.44 &#x000b1; 15.70</td><td align="center" rowspan="1" colspan="1">73.75 &#x000b1; 14.80</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Absolute change &#x00394;Scr</td><td align="center" rowspan="1" colspan="1">&#x02212;5.01 &#x000b1; 11.07</td><td align="center" rowspan="1" colspan="1">&#x02212;1.85 &#x000b1; 10.47</td><td align="center" rowspan="1" colspan="1">&#x02212;4.11 &#x000b1; 9.17</td><td align="center" rowspan="1" colspan="1">0.304</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;
<italic>P</italic> value</td><td align="center" rowspan="1" colspan="1">0.008</td><td align="center" rowspan="1" colspan="1">0.203</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic>P</italic> value was the comparison of the group between Baseline and Post procedural. <italic>P</italic>&#x02032; value was the comparison among groups.</p></fn></table-wrap-foot></table-wrap></floats-group></article>